Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ... recently resubmitted the BLA for Linvoseltamab, our BCMAxCD3 bispecific for relapsed/refractory multiple myeloma following ...

Regeneron Pharmaceuticals ... that we have recently resubmitted the BLA for Linvoseltamab, our BCMAxCD3 bispecific for relapsed/refractory multiple myeloma following the resolution of third ...

and BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies under Bispecific Antibodies. What Is The Regional Analysis Of B Cell Maturation Antigen BCMA Targeted Therapies Market?

Fresh from claiming its first bispecific ... include Regeneron's odronextamab, Genmab/AbbVie's epcoritamab, and Roche's mosunetuzumab and glofitamab. Turning to the CD28 programme, the company ...

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

"CD28 co-stimulatory bispecific antibodies are designed to boost T cell-mediated tumor killing and overcome T cell exhaustion in the solid tumor microenvironment. In preclinical studies ...

Rondo Therapeutics Presents Preclinical Data at ASCO GU for its Novel CD28 x Nectin-4 Costimulatory Bispecific Antibody for Advanced Bladder Cancer - Company plans to initiate a Phase 1/b trial in ...

ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic ...